UK markets open in 3 hours 7 minutes

Genmab A/S (0MGB.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
2,581.26-9.88 (-0.38%)
At close: 05:18PM GMT
Full screen
Previous close2,591.14
Open2,567.00
BidN/A x N/A
AskN/A x N/A
Day's range2,559.00 - 2,574.00
52-week range2,559.00 - 2,574.00
Volume3,075
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well as the Company’s subsidiaries and 5,138 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted sto

  • Globe Newswire

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

    Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio

  • Globe Newswire

    Correction to Company Announcement No. 1 of January 3, 2023

    Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr